CN103664954A - Compounds for treating traumatic brain injury diseases and application thereof - Google Patents
Compounds for treating traumatic brain injury diseases and application thereof Download PDFInfo
- Publication number
- CN103664954A CN103664954A CN201210341993.XA CN201210341993A CN103664954A CN 103664954 A CN103664954 A CN 103664954A CN 201210341993 A CN201210341993 A CN 201210341993A CN 103664954 A CN103664954 A CN 103664954A
- Authority
- CN
- China
- Prior art keywords
- preparation
- compound
- brain injury
- traumatic brain
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000030886 Traumatic Brain injury Diseases 0.000 title claims abstract description 44
- 230000009529 traumatic brain injury Effects 0.000 title claims abstract description 40
- 150000001875 compounds Chemical class 0.000 title claims abstract description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 56
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims description 33
- 238000002347 injection Methods 0.000 claims description 15
- 239000007924 injection Substances 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 12
- -1 polyoxyethylene Polymers 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 239000003405 delayed action preparation Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 5
- 238000007911 parenteral administration Methods 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 4
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 150000008065 acid anhydrides Chemical class 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000412 dendrimer Substances 0.000 claims description 2
- 229920000736 dendritic polymer Polymers 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 239000011806 microball Substances 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 229920000570 polyether Polymers 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000005022 packaging material Substances 0.000 claims 1
- 150000004291 polyenes Chemical class 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 9
- 241001465754 Metazoa Species 0.000 description 25
- 208000027418 Wounds and injury Diseases 0.000 description 23
- 230000006378 damage Effects 0.000 description 20
- 230000002490 cerebral effect Effects 0.000 description 18
- 208000014674 injury Diseases 0.000 description 16
- 206010052428 Wound Diseases 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 10
- 229960003699 evans blue Drugs 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 102000019197 Superoxide Dismutase Human genes 0.000 description 7
- 108010012715 Superoxide dismutase Proteins 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000008733 trauma Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 206010019196 Head injury Diseases 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 4
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical group O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960000502 poloxamer Drugs 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 210000003625 skull Anatomy 0.000 description 4
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 3
- 206010048962 Brain oedema Diseases 0.000 description 3
- 208000022306 Cerebral injury Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
- 208000006752 brain edema Diseases 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000012982 microporous membrane Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229960002009 naproxen Drugs 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- 210000000944 nerve tissue Anatomy 0.000 description 3
- 239000013618 particulate matter Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000002510 pyrogen Substances 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- JKPISQIIWUONPB-HNNXBMFYSA-N (-)-stepholidine Chemical compound C1CN2CC(C(=C(O)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(O)=C2 JKPISQIIWUONPB-HNNXBMFYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 208000034693 Laceration Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000009519 contusion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 229960004526 piracetam Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- HHFBDROWDBDFBR-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 HHFBDROWDBDFBR-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- JOAFLJYYCKDRBM-UHFFFAOYSA-N C[n](cc1)cc1C1=NC2C(Sc3cc4cccnc4cc3)=N[I]=C2C=C1 Chemical compound C[n](cc1)cc1C1=NC2C(Sc3cc4cccnc4cc3)=N[I]=C2C=C1 JOAFLJYYCKDRBM-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- BCZUAADEACICHN-UHFFFAOYSA-N SGX-523 Chemical compound C1=NN(C)C=C1C1=NN2C(SC=3C=C4C=CC=NC4=CC=3)=NN=C2C=C1 BCZUAADEACICHN-UHFFFAOYSA-N 0.000 description 1
- 241000220287 Sedum rubrotinctum Species 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- YYLKKYCXAOBSRM-JXMROGBWSA-N [4-[(e)-2-(1h-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone Chemical compound C=1C=C(\C=C\C=2C3=CC=CC=C3NN=2)C=CC=1C(=O)N1CCNCC1 YYLKKYCXAOBSRM-JXMROGBWSA-N 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003321 atomic absorption spectrophotometry Methods 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N ethyl butyrate Chemical compound CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- ZUVCYFMOHFTGDM-UHFFFAOYSA-N hexadecyl dihydrogen phosphate Chemical class CCCCCCCCCCCCCCCCOP(O)(O)=O ZUVCYFMOHFTGDM-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007925 intracardiac injection Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- LYRFLYHAGKPMFH-UHFFFAOYSA-N octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(N)=O LYRFLYHAGKPMFH-UHFFFAOYSA-N 0.000 description 1
- 229940038384 octadecane Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000003455 parietal bone Anatomy 0.000 description 1
- 210000001152 parietal lobe Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000141 poly(maleic anhydride) Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses compounds, and a pharmaceutical composition and new application thereof in preparing medicines for treating traumatic brain injury diseases. The compounds for treating traumatic brain injury diseases can have very obvious effect.
Description
Technical field
The present invention relates to three kinds of compound and pharmacologically acceptable salt and its analogues for the treatment of traumatic brain injury disease, the pharmaceutical composition of being prepared by above-claimed cpd and pharmacologically acceptable salt thereof and its analogue, and described compound or pharmaceutically acceptable salt thereof and the purposes of analogue in the medicine of preparation treatment traumatic brain injury disease thereof.
Background technology
In recent years, development and the extensive application of modernization mechanicalness equipment in productive life due to communications and transportation, the incidence of traumatic brain injury is rising, disability rate therefore and mortality ratio are in continuous increase, according to nearest epidemiology survey data, show, the sickness rate of China's traumatic brain injury is in every 100,000 people, to surpass 100 people, and its lethal disability rate is first, and levels of thyroid hormone in craniocerebral trauma patients has accounted for 20%.Although the progress along with medical technology, the Level of first-aid treatment of traumatic brain injury improves a lot, but in traumatic brain injury, mortality ratio is still located a high position so far, also can produce very serious sequela, it is the important injury of serious harm human health, this sick feature is that generation reason is more, damage is serious, clinical application medicine is also more, but the result for the treatment of of most drug performance is fainter, desirable not to the utmost, need a kind of medicine of very effectively treating comparatively all sidedly traumatic brain injury badly.
Traumatic brain injury is mainly clashed and is caused by head, and serious traumatic brain injury can destroy bone, damage skin of head, tractive, distortion or tear blood vessel, nerve and the hetero-organization thereof in brain.Be subject to after more serious destruction, will cause bleeding, oedema.Intracranial hemorrhage and with cerebral edema, cranial cavity content is increased, intracranial tissue and blood vessel sustain damage, and cerebral tissue further destroys.The reason of traumatic brain injury is varied, and the harm bringing is all maximum.In the treatment of traumatic brain injury, owing to not having clinically a kind of medicine effectively to treat, so the effect after morbidity treatment can only be different because of state of an illness weight, what have can recover, and what have disables, some death.The factor that affects prognosis depends primarily on damage which cerebral tissue, injury severity score and treatment measure and medication.Many brain functions are by the different zones shared of cerebral tissue, and the function that the cerebral tissue not coming to harm can compensatoryly be partially damaged, can partly recover.Not having clinically in the situation of active drug at present, for the treatment of traumatic brain injury, is generally that multi-medicament drug combination is treated.Widely application has a morphine similar drug, for example Rutundine, l-stepholidine, Naproxen Base, acetylsalicylic acid, Ibuprofen BP/EP, these medicines act as master to calm, therapeutic action is very limited, also give diphenhydramine, promethazine, trichloro-butyl alcohol etc., it can cause cental system toxicity, drowsiness or serious anaphylaxis, and effect is also very general; Some neuroprotectives are very slow to the treatment onset of traumatic brain injury, act on also very limitedly, often cannot reduce the mortality ratio of traumatic brain injury, often as adjuvant therapy medicaments.Some Chinese patent medicines, such as sedative and heart-invigorating pill, gastrodini, cow-bezoar bolus for resurrection etc., acts on slow and limited.
Totally it seems, because the pathogenic factor of traumatic brain injury is many, in many clinical treatment medicines, both do not had very effectively, also there is no extensive therapeutic action.And along with social high speed development, the diversification of traumatic brain injury conditions of patients of today, the adaptability of medicine and result for the treatment of are all not so good as in the past.
The inventor is surprised to find that one group of compound and similar compound or its pharmacologically acceptable salt thereof the purposes in the medicine of preparation treatment traumatic brain injury disease.For this group compounds for treating traumatic brain injury, there is no report at present.
Summary of the invention
The invention provides the one group of compound or pharmaceutically acceptable salt thereof that can treat traumatic brain injury disease, and analogue, the structure of described compound is as follows:
Compound (A);
Compound (C).
The present invention also provides a kind of pharmaceutical composition, and it comprises compound (A), (B) or (C); Said composition can also comprise auxiliary material etc.Described pharmaceutical composition can be through topical, and the various preparations of gastrointestinal administration or parenteral administration, comprise ordinary preparation, controlled release preparation, targeting preparation etc.Described controlled release preparation comprises superpolymer or film material, described superpolymer is selected from: one or more in polylactic-co-glycolic acid, poly-acid anhydrides, polyoxyalkylene, polymeric amide, polyester, polyacrylic resin, polyethers, polyphosphonitrile or glycan, or be selected from the multipolymer between the different monomers of described superpolymer, preferably, described superpolymer is selected from: poly lactic coglycolic acid, lactic-co-glycolic acid-glycol copolymer, PGA, glycollide rac-Lactide-ethylene glycol-glycollide rac-Lactide triblock copolymer, polyoxyethylene glycol, sebacic anhydride-glycol copolymer, octadecane diacid acid anhydride-ethylene glycol segmented copolymer, poly butyric ester, polybutylcyanoacrylate, poly(lactic acid), polymaleic anhydride, poly sebacic polyanhydride, polyvinyl alcohol, NIPA-acrylic copolymer, chitosan, polyethersulfone, Mierocrystalline cellulose, dextran, alginates, dextran, hyaluronic acid, gelatin, poloxamer, Fibrinogen, one or more in albumin or collagen protein etc.Described film material comprises that Yelkin TTS, fabaceous lecithin, phosphatidylethanolamine, cholesterol, kephalin, dipalmitoyl phosphatidylcholine, distearoyl phosphatidylcholine, Glycocholate sodium, Yolk lecithin, phosphatidyl silk amino acid, phosphatidylinositols, sphingomyelin, sphingomyelin, two Cetyl Phosphates, two Pork and beans acyl Yelkin TTS, stearylamide, phosphatidic acid, phosphatidylserine etc. comprise natural or synthetic phosphatide, lipoid or its combination.
The present invention also provides compound (A), (B) or (C) or its pharmacologically acceptable salt and the purposes of analogue in the medicine of preparation treatment traumatic brain injury disease thereof.Described purposes comprise by compound (A), (B) (C) or its pharmacologically acceptable salt and analogue thereof be prepared into through topical, the various preparations of gastrointestinal administration or parenteral administration, comprise that ordinary preparation, controlled release preparation, targeting preparation etc. treat for traumatic brain injury animal model.Described local administration preparation is the powder injection through head administration, aqueous injection, microball preparation, nanometer formulation, Liposomal formulation, dendrimer preparation, aqueogel etc.; Described gastrointestinal administration preparation is tablet, capsule, powder, pill, granule, emulsion etc.; Described parenteral administration preparation is the formulation of suitable intravenous injection, intramuscular injection, intracardiac injection, subcutaneous injection, bone marrow injection, transdermal administration, mucosa delivery and inhalation.The dosage of described medicine is 0.1mg-500mg.
The head serious disease that traumatic brain injury causes due to external world damage, it requires prosecution rapidly, causes, also or the traumatic brain injury that causes of the multiple position of head all can have better performance to have treatment meaning to this type of disease for many reasons.Traumatic brain injury is difficult to sort out; cannot say which kind disease it belongs to; it is a kind of traumatism; be again the disease of a kind of blood vessel, tissue, nerve, skin, the concurrent damage of bone, usually also with infection, a lot of medicines are all only for a part, to treat simultaneously; therefore effect is bad; because the single often overall onset for the treatment of approach is very slow, be often that medicine does not also have enough time to play a role, patient is with regard to dead.When carrying out comparatively serious traumatic brain injury experimentation on animals, during medication, animal is usually just dead after just modeling.The invention of this group, the medicine of mentioning owing to may for number of ways, traumatic brain injury being treated simultaneously, blood vessel, brain inner tissue, nerve, skin and skeletal injury are recovered to have very great therapeutic action, because blood vessel, tissue, nerve, skin and bone are subject to pharmacological agent jointly, collaborative recovery, therefore promptly onset.Contriver finds pleasantly surprisedly, and dead (comprising the animal model that traumatic brain injury is very serious) all do not occur all traumatic brain injury animals after medication, and the far super positive control drug of recovery.
Embodiment
The present invention's compound used can be purchased SGX-523, and KW-2449 and MLN-8054 also can be prepared according to relevant disclosed preparation method, and it does not limit the scope of the invention.Below in conjunction with embodiment, the present invention is further explained.
Effect embodiment
Described compd A structure is:
Compound (A);
Described compd B structure is:
compound (B);
Described Compound C structure is:
Compound (C).
Preparation containing compd A lyophilized injectable powder:
1. get N.F,USP MANNITOL, phosphatide, glycerine, cyclodextrin derivative and poloxamer 100mg and 900mg formula (A) altogether
Compound mixes and makes it and dissolves in water for injection;
2. after mixing dissolving, after stable, first use 0.45um millipore filtration coarse filtration, then use 0.2um filtering with microporous membrane;
3. be distributed into little cillin bottle, add other lyophilized vaccines and auxiliary material;
4. carry out procedural freeze-drying;
5. carry out the corresponding inspections such as pyrogen, aseptic, visible foreign matters, particulate matter, stand-by after all meeting the requirements.
Preparation containing compd B lyophilized injectable powder:
1. get N.F,USP MANNITOL, phosphatide, glycerine, cyclodextrin derivative and poloxamer 100mg and 900mg formula (B) altogether
Compound mixes and makes it and dissolves in water for injection;
2. after mixing dissolving, after stable, first use 0.45um millipore filtration coarse filtration, then use 0.2um filtering with microporous membrane;
3. be distributed into little cillin bottle, add other lyophilized vaccines and auxiliary material;
4. carry out procedural freeze-drying;
5. carry out the corresponding inspections such as pyrogen, aseptic, visible foreign matters, particulate matter, stand-by after all meeting the requirements.
Preparation containing Compound C lyophilized injectable powder:
1. get N.F,USP MANNITOL, phosphatide, glycerine, cyclodextrin derivative and poloxamer 100mg and 900mg formula (C) altogether
Compound mixes and makes it and dissolves in water for injection;
2. after mixing dissolving, after stable, first use 0.45um millipore filtration coarse filtration, then use 0.2um filtering with microporous membrane;
3. be distributed into little cillin bottle, add other lyophilized vaccines and auxiliary material;
4. carry out procedural freeze-drying;
5. carry out the corresponding inspections such as pyrogen, aseptic, visible foreign matters, particulate matter, stand-by after all meeting the requirements.
1 compound (A-C) and similar compound thereof or the provide protection of its pharmacologically acceptable salt to rabbit cerebral trauma brain injury
1.1 laboratory animal and grouping
Healthy adult rabbit is divided into 6 groups at random, 10 every group.Be Normal group, model group, compd A group injection liquid, compd B group injection liquid, Compound C group injection liquid (described injection liquid is that the powder injection of getting the compd A-C of above-mentioned preparation is made with physiological saline solution), and positive drug Piracetam Injection.Normal group is not caused injury, and only in volume crown drill hole, right side, all causes injury for other several groups.
1.2 experimental technique
1.2.1 model preparation
Auricular vein is injected 3% vetanarcol 1ml.kg
-1.After anesthesia, through auricular vein, inject 2.5% Evans Blue (Evans blue, EB) 1ml.kg again
-1.The rabbit position of bowing is fixed on experimentation on animals operator's console, and hair is shaved at rabbit volume top, center sagittal otch, and otch is about 3cm.The boring of right volume top, stings out a diameter 0.8cm similar round bone window, keeps dura mater complete.Be used for placing cranium Doppler (TCD) probe.The seat cushion of causing injury is placed on the parietal bone of left side, and 1kg metal weight is placed in apart from skull 50cm eminence freely falling body and is discharged, and metal is hit on the pad of causing injury, and hitting power conducts to skull, causes local depressed fracture of skull and contusion and laceration of brain.Make rabbit produce bone, many-sided damage in skin, blood vessel, tissue and brain.
1.2.2 methods for the treatment of and index detect
Medicine group intravenous injection relative medicine immediately after modeling, compd A, B, C group are injected respectively A, B, C injection liquid, positive control drug treated animal injection Piracetam Injection (1.5mg.kg
-1), blank group gives isopyknic physiological saline.5min before cranium Doppler (TCD) is surveyed each treated animal wound and after wound, 30min, 1h, 2h,, 3h, the arteria cerebri media systolic blood Flow Velocity (Vs) of 4h, end diastolic velocity (Vd) and PI (PI), and survey Evans Blue (EB) content by methane amide infusion method, with atomic absorption spectrophotometry, survey Ca
2+.
1.3 statistical method
Each is organized data and represents by mean ± standard deviation, relatively adopts t check between group, and there is statistical significance P≤0.05 for difference.
1.4 result
1.4.1 the behavior of rabbit after causing injury changes
Model group animal hinders latter 5 and occurs breathlessness, needs can recover autonomous respiration after human assistance breathing, occurs that breathing shoals slack-off after Some Animals wound, and heartbeat is slow, improvement voluntarily after 2 minutes.After all animal wounds, all there is irritated, tic in various degree.
1.4.2 CBFV (CBV) and PI (PI) change
1.4.2.1Vs variation
Vs value no significant difference before each treated animal cerebral trauma.Model group animal craniocerebral injury Vs value starts to reduce, from 30min hindering, before wound, obviously reduce, each organizes injured animal at 30min, 1hVs hinders front obvious reduction, medicine A, B, C group after wound medication after 2 hours Vs value raise gradually, with there was no significant difference before wound, and after wound, 3h, 4h Vs value are compared with model group obviously rising (P < 0.01) (in Table 1) of Vs value in the same time, and successful is better than and contrasts positive drug group.Its Chinese traditional medicine A, B, C group rising speed is fast, illustrates that medicine may directly enter target organ, corresponding lesion location, and onset is very fast.
Comparison (n=10, the cm.s of Vs value before and after each treated animal cerebral trauma of table 1
-1)
With control group comparison
#p < 0.05
##p < 0.01, with model group comparison
*p < 0.05
*p < 0.01
1.4.2.2Vd variation
Vd value no significant difference before each treated animal wound.Model group craniocerebral injury Vd value obviously reduces before wound from 5min hindering, reaches Schwellenwert to 4h, and with the obviously reduction (P < 0.01) of comparing also of Normal group Vd value in the same time; 30min after medicine A, B, C treatment group animal wound, 1h Vd value obviously reduces before hindering, and 3h after wound, 4h, Vd value compared with model group in the same time Vd value obviously raise (P < 0.05 or P < 0.01) (in Table 2), and all show than positive drug group have better result for the treatment of (P < 0.05) after medicine A, B, the medication of C group.
Comparison (n=10, the cm.s of Vd value before and after each treated animal cerebral trauma of table 2
-1)
With control group comparison
#p < 0.05
##p < 0.01, with model group comparison
*p < 0.05
*p < 0.01
1.4.2.3PI variation
PI value no significant difference before each treated animal wound.Model group PI value from 5min hindering significantly raises before hindering, and reaches maximum to 4h, and with the obviously rising (P < 0.05 or P < 0.01) of comparing also of Normal group PI value in the same time; Medicine A, B, C treatment group animal 5min to 30min PI value from hindering significantly raises before hindering.3h, before 4h and wound, comparing difference is without significance, and model group PI value significantly reduces (P < 0.05 or P < 0.01) (in Table 3) more in the same time from 30min hindering, after medicine A, B, the medication of C group, effect is far better than positive drug control group.
The comparison (n=10) of PI value before and after each treated animal cerebral trauma of table 3
With control group comparison
#p < 0.05
##p < 0.01, with model group comparison
*p < 0.05
*p < 0.01
1.4.3 cerebral tissue EB content
1.4.3.1EB typical curve
Utilize optical density(OD) (X) and the corresponding EB content (Y) of each standard pipe to carry out straight-line regression, obtain equation EB relation equation.
1.4.3.2 cerebral tissue EB content
Each treated animal causes craniocerebral injury 4h, and cerebral tissue EB content is all apparently higher than Normal group (P < 0.01).With model group comparison, each medication therapy groups EB content all obviously reduces (P < 0.05 or P < 0.01) (in Table 4).Result shows, through pharmacological agent, can make blood-brain barrier permeability reduce, and can alleviate the blood vessel source cerebral edema of craniocerebral injury.
1.4.4 cerebral tissue Ca
2+content
With Normal group comparison, the Ca of model group animal brain
2+content obviously raise (P < 0.01); With model group comparison, medicine A, B, C treatment group Ca
2+content obviously reduces (P < 0.01), the Ca after A, B, C treatment
2+content and Normal group be (in Table 4) quite.Illustrate that medicine A, B, C can better suppress the generation of the calcium overload that causes due to brain injury, thereby play the provide protection to cerebral tissue.
Table 4 each treated animal cerebral tissue EB and Ca
2+content (n=10)
With control group comparison
##p < 0.01, with model group comparison
*p < 0.05
*p < 0.01
2 medicine A, B, the C therapeutic action after to experimental rat traumatic brain injury
2.1 laboratory animal and grouping
Healthy Wistar rat, male, 290-310g, experiment is divided into 6 groups, 30 every group, is divided into Normal group, model group, compd A group, compd B group, Compound C group and positive drug Naproxen Base group.
2.2 experimental technique
2.2.1 cerebral trauma animal model
Cerebral trauma animal model adopts the Feeney method of improvement, and each organizes rat 12h fasting in the preoperative, freely drinks water, and rat is with vetanarcol (30mg.kg
-1) anaesthetize, be fixed on stereotactic apparatus rat is prostrate, head cropping, routine disinfection drape, operation head hits exactly the sagittal of taking back and cuts skin, appear left top, peel off periosteum and expose skull, the surging force of causing injury is 800g/cm, and cone is maximum sink apart from 3mm, cause left parietal lobe contusion and laceration of brain, the area of causing injury is 3mm * 3mm.Rat all recovers diet in operation in latter 12 hours.
2.2.2 each treated animal is processed
After modeling, medicine group gives relative medicine (3mg.kg immediately
-1), control group gives isopyknic physiological saline.After experiment the 5th day, with 4% paraformaldehyde (4 ℃, pH7.4) through aorta ascendens perfusion, fixedly after the about 30min of brain, take out rapidly hemicerebrum, immerse in above-mentioned stationary liquid.
2.2.3 hemicerebrum moisture determination
Get 10 samples for every group, after taking-up hemicerebrum, with electronic analytical balance, claim hemicerebrum weight in wet base, then put into 100 ℃ of baking boxs baking 24h, then claim dry weight with electronic analytical balance.By dry wet method, calculate brain water content, i.e. brain water content=(weight in wet base-dry weight)/weight in wet base * 100%.
2.2.4 serological index detects
Utilize xanthine oxidase to detect serum superoxide dismutases (SOD) activity; Utilize thiobarbituricacidα-method to measure Serum MDA (MDA) concentration; Utilize ELISA method to measure serum il-1 β (IL-1 β), tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) concentration.
2.3 statistical method
Each is organized data and represents by mean ± standard deviation, relatively adopts t check between group, and P < 0.05 has statistical significance for difference.
2.4 result
2.4.1 the impact of medicine on Rats with Cerebral Injury brain hemisphere water content
Result shows (in Table 5), and Normal group brain water content is 75.34%, and model group brain water content is 80.98%.Two groups of comparing differences remarkable (p < 0.001) illustrate that this model can cause the obvious oedema of cerebral tissue.With model group comparison, medicine A, B, C group have and obviously alleviate cerebral edema effect (p < 0.01).
The impact (n=10) of table 5 medicine on traumatic brain injury in rats brain hemisphere water content
With control group comparison
###p < 0.001, with model group comparison
*p < 0.05
*p < 0.01
2.4.2 the impact of medicine on Rats with Cerebral Injury SOD in serum, MDA
The results are shown in Table 6, with Normal group comparison, model group SOD is active obviously to be reduced, and MDA obviously increases (P < 0.01).With model group comparison, medicine A, B, the C group SOD that can obviously raise in serum is active, reduces MDA (P < 0.01 or P < 0.05).Though and the Naproxen Base group SOD that also can raise in serum is active and reduce MDA, but effect differs more (P < 0.05) compared with medicine A, B, C group.
Table 6 different dosing group is on the impact of Rats with Cerebral Injury SOD in serum, MDA (n=10)
With control group comparison
##p < 0.01, with model group comparison
*p < 0.05
*p < 0.01
In sum, visible medicine A, B, C have very large therapeutic action on treatment traumatic brain injury, can to brain injury, carry out strong treatment from many aspects.
Claims (10)
1. a class can be treated the compound or pharmaceutically acceptable salt thereof of traumatic brain injury disease, and analogue, and the structure of described compound is as follows:
Compound (A);
Compound (C).
2. a pharmaceutical composition, it comprises compound claimed in claim 1 and pharmacologically acceptable salt and its analogue.
3. the pharmaceutical composition of claim 2, it can be ordinary preparation, controlled release preparation, targeting preparation etc., the packaging material choosing of described controlled release preparation is white: the natural or synthetic superpolymer of one or more in polylactic-co-glycolic acid, polyoxyethylene glycol, poly-acid anhydrides, polymeric amide, polyester, polyene, polyethers, polyphosphonitrile or glycan, or natural or synthetic phosphatide, lipoid or its combination.
4. compound and pharmacologically acceptable salt thereof and its analogue purposes in the medicine of preparation treatment traumatic brain injury disease described in claim 1.
5. the purposes of claim 4, the treatment of described traumatic brain injury disease comprises treatment traumatic brain injury, alleviates the related symptoms of traumatic brain injury.
6. the purposes of claim 5, described compound and pharmacologically acceptable salt thereof and its analogue are prepared into through topical, the various preparations of gastrointestinal administration or parenteral administration.
7. the purposes of claim 6, described preparation comprises ordinary preparation, controlled release preparation, targeting preparation etc.
8. the purposes of claim 6, described local administration preparation is the powder injection through head administration, aqueous injection, microball preparation, nanometer formulation, Liposomal formulation, dendrimer preparation, polyethyleneglycol modified preparation, aqueogel etc.
9. the purposes of claim 6, described gastrointestinal administration preparation is tablet, capsule, powder, pill, granule, emulsion etc.
10. the purposes of claim 6, described parenteral administration preparation is the formulation of suitable intravenous injection, intramuscular injection, subcutaneous injection, bone marrow injection, transdermal administration, mucosa delivery and inhalation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210341993.XA CN103664954A (en) | 2012-09-17 | 2012-09-17 | Compounds for treating traumatic brain injury diseases and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210341993.XA CN103664954A (en) | 2012-09-17 | 2012-09-17 | Compounds for treating traumatic brain injury diseases and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103664954A true CN103664954A (en) | 2014-03-26 |
Family
ID=50303820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210341993.XA Pending CN103664954A (en) | 2012-09-17 | 2012-09-17 | Compounds for treating traumatic brain injury diseases and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103664954A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103664907A (en) * | 2012-09-25 | 2014-03-26 | 杨子娇 | Compounds for treating narrow chamber angle and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101553490A (en) * | 2006-10-23 | 2009-10-07 | Sgx药品公司 | Bicyclic triazoles as protein kinase modulators |
| CN101653607A (en) * | 2008-08-19 | 2010-02-24 | 鼎泓国际投资（香港）有限公司 | Pharmaceutical composition containing hepatocyte growth factor receptor inhibitor and mitogen extracellular kinase inhibitor and application thereof |
| EP2425830A1 (en) * | 2010-09-03 | 2012-03-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synergistic drug combination for the treatment of cancer |
-
2012
- 2012-09-17 CN CN201210341993.XA patent/CN103664954A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101553490A (en) * | 2006-10-23 | 2009-10-07 | Sgx药品公司 | Bicyclic triazoles as protein kinase modulators |
| CN101653607A (en) * | 2008-08-19 | 2010-02-24 | 鼎泓国际投资（香港）有限公司 | Pharmaceutical composition containing hepatocyte growth factor receptor inhibitor and mitogen extracellular kinase inhibitor and application thereof |
| EP2425830A1 (en) * | 2010-09-03 | 2012-03-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synergistic drug combination for the treatment of cancer |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103664907A (en) * | 2012-09-25 | 2014-03-26 | 杨子娇 | Compounds for treating narrow chamber angle and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101859486B1 (en) | Sublingual Dexmedetomidine Compositions and Methods of Use Thereof | |
| CA3037089C (en) | Sublingual pharmaceutical composition of edaravone and (+)-2-borneol | |
| EP3694489A2 (en) | Methods and compositions for topical delivery | |
| WO2003013589A1 (en) | Isulin-containing oral spray and the preparation method thereof | |
| Gangurde et al. | Lamotrigine lipid nanoparticles for effective treatment of epilepsy: a focus on brain targeting via nasal route | |
| CN103664936A (en) | Compounds for treating traumatic brain injury diseases and application thereof | |
| CN108912349A (en) | Polylactic acid microsphere and preparation method thereof and the application in medicament slow release | |
| JPH01503146A (en) | Methods of treating body tissue and administering medicines to body tissue | |
| WO2009015561A1 (en) | The use of leonurine and compositions thereof | |
| CN101422431B (en) | Insulation administration preparation through nose | |
| CN1997383B (en) | Aequorin-containing compositions and methods of using same | |
| CN116099007A (en) | Pamoate sustained-release composition of local anesthetic and alkaloid | |
| US6623732B1 (en) | Pharmaceutical formulation for nasal administration | |
| CN110870858A (en) | Pharmaceutical compositions comprising organic acid acidifying agents and conventional ineffective compounds and uses thereof | |
| CN103664954A (en) | Compounds for treating traumatic brain injury diseases and application thereof | |
| CN103664798A (en) | Compounds for treating traumatic brain injury diseases and application thereof | |
| CN103655575A (en) | Compounds for treating traumatic brain injury diseases and application thereof | |
| CN103655572A (en) | Compounds for treating traumatic brain injury diseases and application thereof | |
| CN103127505B (en) | Purposes of the statin compound as treatment diabetes topical drug | |
| CN103655577A (en) | Compounds for treating traumatic brain injury diseases and application thereof | |
| CN103804302A (en) | Compound for treating traumatic brain injury disease and use thereof | |
| CN103664935A (en) | Compounds for treating traumatic brain injury diseases and application thereof | |
| CN103664879A (en) | Compounds for treating traumatic brain injury diseases and application thereof | |
| CN112438942A (en) | Pharmaceutical composition containing alkalizer and its synergist and its application | |
| CN103784400A (en) | Novel oral micelle preparation of pegylated phosphatide-entrapped insulin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140326 |